References: Skin reactions from cancer treatment in palliative care

Chan RJ, Webster J, Chung B, Marquart L, Ahmed M, Garantziotis S. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer 2014;14:53. https://www.ncbi.nlm.nih.gov/pubmed/24484999

Choi J, Anderson R, Blidner A, Cooksley T, Dougan M, Glezerman I, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Support Care Cancer 2020;28(12):6119-28. https://www.ncbi.nlm.nih.gov/pubmed/32856211

eviQ. Acneiform rash (papulopustular rash) associated with epidermal growth factor receptor (EGFR) inhibitors. St Leonards, NSW: Cancer Institute NSW. 2022; Updated 20 May 2022. https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/hair-skin-and-nails/1241-acneiform-rash-associated-with-egfr-inhibitor

eviQ. Acute graft versus host disease (aGVHD). St Leonard, NSW: Cancer Institute NSW. 2021; Updated 27 April 2021. Accessed https://www.eviq.org.au/clinical-resources/bmt-cellular-therapies/3815-acute-graft-versus-host-disease-agvhd

eviQ. Chronic graft versus host disease (cGVHD). St Leonards, NSW: Cancer Institute NSW. 2021; Accessedhttps://www.eviq.org.au/clinical-resources/bmt-cellular-therapies/3829-chronic-graft-versus-host-disease-cgvhd

eviQ. Hand-foot syndrome (HFS) - palmar-plantar erythrodysaesthesia (PPE) associated with chemotherapeutic agents. St Leonards, NSW: Cancer Institute NSW. 2021; Updated 30 July 2021. Accessed https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/hair-skin-and-nails/1416-hand-foot-syndrome-associated-with-chemothera

Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl_4):iv119-iv42. https://www.ncbi.nlm.nih.gov/pubmed/28881921

Hansen ED, Wang X, Case AA, Puzanov I, Smith T. Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. J Pain Symptom Manage 2018;56(3):460-72.https://www.ncbi.nlm.nih.gov/pubmed/29792979

Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev 2020;14(1):442. https://www.ncbi.nlm.nih.gov/pubmed/32431787

Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fernandez-Penas P, Santini D, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines(☆). Ann Oncol 2021;32(2):157-70. https://www.ncbi.nlm.nih.gov/pubmed/33248228

Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer 2013;21(10):2933-48. https://www.ncbi.nlm.nih.gov/pubmed/23942595

Zheng YF, Fu X, Wang XX, Sun XJ, He XD. Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients. World J Clin Cases 2021;9(33):10075-87. https://www.ncbi.nlm.nih.gov/pubmed/34904077